Last reviewed 2026-04-22 · How we verify

CT-P47 PFS (tocilizumab)

CT-P47 is a monoclonal antibody that blocks interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases.

CT-P47 is a monoclonal antibody that blocks interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases. Used for Rheumatoid arthritis, Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.

At a glance

Mechanism of action

CT-P47 is a biosimilar of tocilizumab, which binds to the IL-6 receptor (both membrane-bound and soluble forms) and inhibits IL-6 signaling. This blocks a key inflammatory cytokine pathway involved in autoimmune and inflammatory conditions. By reducing IL-6-mediated inflammation, it suppresses disease activity in conditions such as rheumatoid arthritis and other inflammatory disorders.

Approved indications

• Rheumatoid arthritis
• Giant cell arteritis
• Polyarticular juvenile idiopathic arthritis

Common side effects

• Infection (including serious infections)
• Elevated liver enzymes
• Neutropenia
• Hyperlipidemia
• Gastrointestinal perforation

Key clinical trials

• A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis (PHASE3)
• A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CT-P47 PFS (tocilizumab) CI brief — competitive landscape report
• CT-P47 PFS (tocilizumab) updates RSS · CI watch RSS
• Celltrion portfolio CI